+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of GDC-4198 alone and combined with giredestrant compared to abemaciclib plus giredestrant in people with locally advanced or metastatic estrogen receptor-positive ER, HER2-negative breast cancer. This study includes two parts Phase Ib to assess safety and how the body processes GDC-4198, and Phase II to compare the activity and safety of the two treatment combinations. Participants benefiting from GDC-4198 in a previous study may continue with this treatment. Participants receive GDC-4198 by mouth either alone or with giredestrant daily in 28-day cycles until unacceptable side effects, disease progression, or loss of benefit. Different dosing levels of GDC-4198 combined with giredestrant are studied, and others receive abemaciclib with giredestrant. Those from the earlier study continuing treatment keep their current dose of GDC-4198. During the study, participants will be regularly monitored for side effects and treatment impact, including disease progression and response rates. Researchers will track adverse events, dose-limiting toxicities, progression-free survival, and overall survival for up to 36 months. Assessments include safety evaluations, pharmacokinetics of GDC-4198, and measuring clinical benefit throughout the trial period.

Age: 18Years +All GendersPhase 1Phase 2
77 locations